Select black men are potential candidates for prostate hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer-a multicenter SEARCH cohort study

Genitourinary Cancer

Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort

Cancer Epidemiol Biomarkers Prev

Liss MA, Zeltser N, Zheng Y, Lopez C, Liu M, Patel Y, Yamaguchi TN, Eng SE, Tian M, Semmes OJ, Lin DW, Brooks JD, Wei JT, Klein EA, Tewari AK, Mosquera JM, Khani F, Robinson BD, Asad M, Troyer DA, Kagan J, Sanda MG, Thompson IM, Boutros PC, Leach RJ

doi: 10.1158/1055-9965.EPI-24-0326

COMMENTED

Genitourinary Cancer

Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk

★ 1 Recommended and commented by Prof. Dr Richard Cathomas, Faculty Member

JAMA Oncol

Tilki D, Chen MH, Wu J, Huland H, Graefen M, Trock BJ, Han M, D'Amico AV

doi: 10.1001/jamaoncol.2025.0110

Gastrointestinal Cancer

Panacreatic cancer risk after benign gallbladder disease: A Swedish population-based cohort study

Eur J Cancer

Radkiewicz C, Ludvigsson JF, Sparrelid E, Emilsson L

doi: 10.1016/j.ejca.2024.115140

Genitourinary Cancer

Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer

Prostate Cancer Prostatic Dis

Incesu RB, Preisser F, Nohe F, Maurer T, Graefen M, Tilki D

doi: 10.1038/s41391-024-00930-z

Genitourinary Cancer

Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study

Prostate Cancer Prostatic Dis

Graff JN, Hoimes CJ, Gerritsen WR, Vaishampayan UN, Elliott T, Hwang C, Ten Tije AJ, Omlin A, McDermott RS, Fradet Y, Tagawa ST, Kilari D, Ferrario C, Uemura H, Jones RJ, Fukasawa S, Peer A, Niu C, Poehlein CH, Qiu P, Suttner L, de Wit R, Schloss C, de Bono JS, Antonarakis ES

doi: 10.1038/s41391-024-00865-5

Further Publications

Residential exposure to solar ultraviolet radiation and risk of childhood hematological malignancies in Switzerland: A census-based cohort study

Int J Cancer

Coste A, Kreis C, Backes C, Bulliard JL, Folly C, Brack E, Renella R, Vernez D, Spycher BD, SNC study group

doi: 10.1002/ijc.35214

Genitourinary Cancer

High interobserver variability of PTEN immunohistochemistry defining PTEN status in low- to intermediate-risk prostate cancer: results of the first German ring trial

Virchows Arch

Hommerding O, Bernhardt M, Kreft T, Scherping A, Abbas M, Baretton G, Bräsen JH, Breyer J, Darr C, Dressler FF, Ellinger J, Erber R, Esposito I, Hartmann A, Hartmann W, Heitplatz B, Kreipe H, Lafos M, Linxweiler J, Lopez-Cotarelo C, Sailer V, Reis H, Saar M, Schildhaus HU, Schlack K, Schmid M, Seidl M, Semjonow A, Sommer U, Stahl PR, Tischler V, Weber F, Wulf AL, Wullich B, Kristiansen G

doi: 10.1007/s00428-024-03999-y

Genitourinary Cancer

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study

Lancet Oncol

Karpinski MJ, Hüsing J, Claassen K, Möller L, Kajüter H, Oesterling F, Grünwald V, Umutlu L, Kleesiek J, Telli T, Merkel-Jens A, Hüsing A, Kesch C, Herrmann K, Eiber M, Hoberück S, Meyer PT, Kind F, Rahbar K, Schäfers M, Stang A, Hadaschik BA, Fendler WP

doi: 10.1016/S1470-2045(24)00326-7

Further Publications

Biopsy-verified vulvar lichen sclerosus and the risk of non-vulvar cancer: A nationwide cohort study

Int J Cancer

Kaderly Rasmussen EL, Hannibal CG, Hertzum-Larsen R, Kjær SK, Baandrup L

doi: 10.1002/ijc.35101

Related content

Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort

Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk

Panacreatic cancer risk after benign gallbladder disease: A Swedish population-based cohort study

Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer

Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study

Residential exposure to solar ultraviolet radiation and risk of childhood hematological malignancies in Switzerland: A census-based cohort study

High interobserver variability of PTEN immunohistochemistry defining PTEN status in low- to intermediate-risk prostate cancer: results of the first German ring trial

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study

Biopsy-verified vulvar lichen sclerosus and the risk of non-vulvar cancer: A nationwide cohort study